论文标题
癌症中侵袭和克隆选择的最小模型
Minimal models of invasion and clonal selection in cancer
论文作者
论文摘要
在本文中,我们开发了癌细胞运动,生长和演变之间关系的最小模型。我们利用空间中单个细胞群的简单模拟来检查侵入性细胞及其周围环境的机械性能的变化如何影响细胞迁移的速度。我们还发现,大病变的生长速率微弱地取决于逃脱细胞的迁移速度,并且对模型中其他随机过程的速率具有更强,更复杂的依赖性,即细胞过渡到运动的速率以及细胞在哪些细胞中停止的反向速率。 为了研究癌变的生长速率和演变如何取决于其几何形状和潜在的健身景观,我们开发了一个分析框架,在该框架中,空间结构是粗粒状的,癌症被视为具有随机迁移事件的连续增长系统。两种方法都结论是,无论大小对单个病变的时间的依赖性如何,整个整体都可以经历迁移驱动的指数增长,并且生长速率和迁移速率之间的关系取决于单个病变的几何约束。我们还发现,线性适应性景观导致合奏的指数增长快,我们可以确定模型的几个重要情况下存在的驱动突变的预期数量。 最后,我们从临床研究中研究了新的低剂量组合化疗的有效性的数据。这使我们能够检验一些关于胰腺癌的生长速率以及现实中进化的速度的重要假设。尽管如此,我们发现抗性突变体的频率太高而无法解释,而无需诉诸于多种药物的跨耐药机制。
In this thesis we develop minimal models of the relationship between motility, growth, and evolution of cancer cells. We utilise simple simulations of a population of individual cells in space to examine how changes in mechanical properties of invasive cells and their surroundings can affect the speed of cell migration. We also find that the growth rate of large lesions depends weakly on the migration speed of escaping cells, and has stronger and more complex dependencies on the rates of other stochastic processes in the model, namely the rate at which cells transition to being motile and the reverse rate at which cells cease to be motile. To examine how the rates of growth and evolution of an ensemble of cancerous lesions depends on their geometry and underlying fitness landscape, we develop an analytical framework in which the spatial structure is coarse grained and the cancer treated as a continuously growing system with stochastic migration events. Both approaches conclude that the whole ensemble can undergo migration-driven exponential growth regardless of the dependence of size on time of individual lesions, and that the relationship between growth rate and rate of migration is determined by the geometrical constraints of individual lesions. We also find that linear fitness landscapes result in faster-than-exponential growth of the ensemble, and we can determine the expected number of driver mutations present in several important cases of the model. Finally, we study data from a clinical study of the effectiveness of a new low-dose combined chemotherapy. This enables us to test some important hypotheses about the growth rate of pancreatic cancers and the speed with which evolution occurs in reality. Despite this, we find that the frequency of resistant mutants is far too high to be explained without resorting to novel mechanisms of cross-resistance to multiple drugs.